(Q36609581)

15 August 2017

Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma (English)

1 reference

cutaneous B-cell lymphoma

15 August 2017

1 reference

1 reference

1 reference

M Wobser

1

1 reference

15 August 2017

H Voigt

2

1 reference

15 August 2017

A O Eggert

3

1 reference

15 August 2017

R Houben

4

1 reference

15 August 2017

C S Kauczok

5

1 reference

15 August 2017

E B Bröcker

6

1 reference

15 August 2017

J C Becker

7

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

96

1 reference

15 August 2017

10

1 reference

15 August 2017

1540-1543

1 reference

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359948

WHO-EORTC classification for cutaneous lymphomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359948

The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359948

Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359948

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359948

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359948

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359948

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359948

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359948

Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis

20 September 2018

1 reference

12 December 2020

CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases

1 reference

12 December 2020

Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603762

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

17473827

1 reference